Compounds as brg1 and brm inhibitors and uses thereof
By developing compounds of general formula (I) as inhibitors of BRM and BRG1, the problem of insufficient research on BRM and BRG1 inhibitors in the prior art has been solved, and effective treatment of BRG1-mutant cancers has been achieved.
CN122404243APending Publication Date: 2026-07-17CHINA PHARM UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- CHINA PHARM UNIV
- Filing Date
- 2026-04-30
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
There is limited research on inhibitors of BRM and BRG1 in existing technologies, and the challenges in cancer treatment caused by BRG1 mutations have not yet been effectively resolved.
Method used
A class of compounds of general formula (I) or pharmaceutically acceptable salts thereof have been developed as inhibitors of BRM and BRG1 to inhibit the ATPase activity of BRM and BRG1. These compounds are prepared in the form of capsules, pills, tablets, granules, injections, etc., and administered orally or by injection.
Benefits of technology
This compound can effectively inhibit the activity of BRM and BRG1, and as an anti-tumor precursor, it can be used to prevent or treat cancer, exhibiting pharmacological activity similar to or better than existing anticancer drugs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122404243A_ABST
Abstract
本发明公开了一类作为BRG1和BRM抑制剂的化合物及其应用，所述化合物具有通式（I）所示结构。本发明化合物对BRG1和 / 或BRM ATP酶活性具有显著抑制作用，可用于制备治疗BRG1 / BRM相关疾病的药物，作为进一步开发为治疗和 / 或预防各种BRG1介导的病症和BRM介导的病症的方法。(Ⅰ)
Need to check novelty before this filing date? Find Prior Art